Copper Mountain Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2010



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Alzheimer's Disease Beyond Abeta (A4)


Organizer(s) JoAnne McLaurin and Tony Wyss-Coray
January 10—15, 2010
Copper Mountain Resort • Copper Mountain, Colorado USA
Abstract Deadline: Sep 15, 2009
Late Abstract Deadline: Oct 13, 2009
Scholarship Deadline: Sep 15, 2009
Early Registration Deadline: Nov 10, 2009

Sponsored by Takeda Pharmaceutical Company Limited

Summary of Meeting:
By 2010 many of the clinical trials presently underway targeting Abeta will have been completed or far enough along the pathway that we will have a better understanding of the benefit and limitations of this approach. This leads us to consider what are the next targets that will need to be addressed to fully treat and prevent Alzheimer’s disease. The objective of this meeting is therefore to stimulate and promote a discussion beyond Abeta as a key factor and therapeutic target in Alzheimer's Disease. This objective will be equally important whether therapeutic approaches targeting Abeta are successful or not, to either complement and expand successful Abeta therapies or to initiate a paradigm shift. In particular, we would like to discuss the generation of alternative models to study Alzheimer's Disease, and highlight several exciting areas of research including the role of synaptic dysfunction, neuronal regeneration, the immune system, and protein degradation in Alzheimer's Disease.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, JANUARY 10

15:00—19:30
Registration

Kokopelli's
18:30—19:30
Refreshments

Kokopelli's
19:30—20:30
Keynote Address I
Meeting has ended...abstracts no longer viewable online.

Big Horn B
* JoAnne McLaurin, University of Toronto, Canada

Dora Games, Neotope Biosciences, USA
Issues and Advances in the Development of Immunotherapeutic Approaches for Alzheimer's Disease

20:30—21:30
Keynote Address II
Meeting has ended...abstracts no longer viewable online.

Big Horn B
* Tony Wyss-Coray, Stanford University School of Medicine, USA

Lennart Mucke, Gladstone Institutes and University of California, San Francisco, USA
Strategies to Block Alzheimer's Disease-Associated Neuronal Dysfunction


MONDAY, JANUARY 11

07:00—08:00
Breakfast

Kokopelli's
08:00—11:00
Remodeling Alzheimer's Disease: An Academic Perspective
Meeting has ended...abstracts no longer viewable online.
Many treatment strategies have been developed for Alzheimer’s disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans?

Big Horn B
* Lennart Mucke, Gladstone Institutes and University of California, San Francisco, USA

Todd Eliot Golde, Mayo Clinic Jacksonville, USA
Preclincial Studies of Alzheimer's Disease and the Treatment versus Prevention Paradox

Bart De Strooper, University College London, UK
Dysregulation of the microRNA network in sporadic Alzheimer's disease

Roxana Octavia Carare, University of Southampton, UK
Perivascular Drainage of Abeta and the Pathology of CAA

William J. Jagust, University of California, Berkeley, USA
Structural and Neurochemical Changes within the CNS during Aging and AD in Aging and AD

09:20—09:40
Coffee Break

Kokopelli's
11:00—13:00
Poster Setup

Big Horn C
11:00
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Big Horn C
16:30—17:00
Coffee Available

Kokopelli's
17:00—19:00
Remodeling Alzheimer's Disease II: An Industry Perspective
Meeting has ended...abstracts no longer viewable online.
Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets.

Big Horn B
* Dora Games, Neotope Biosciences, USA

Marc Tessier-Lavigne, Stanford University, USA
APP-DR6 Signaling in Axon Development, Regeneration, and Degeneration

Menelas N. Pangalos, AstraZeneca, UK
Beyond Abeta Based Therapies: Developing Novel Modulators of Neurotransmission

Amie L. Phinney, Solvay Pharmaceuticals, Netherlands
Short Talk: The Impact of Biomarkers on Alzheimer’s Disease Drug Discovery

19:00—20:00
Social Hour with Lite Bites

Kokopelli's
19:30—22:00
Poster Session 1

Big Horn C

TUESDAY, JANUARY 12

07:00—08:00
Breakfast

Kokopelli's
08:00—11:00
Alzheimer's and Synaptic/Neuronal Disfunction
Meeting has ended...abstracts no longer viewable online.
How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present.

Big Horn B
* William E. Van Nostrand, Stony Brook University, USA

Sheena Josselyn, Hospital for Sick Children, Canada
Cognitive Deficits in a Mouse Model of Alzheimer's Disease: The Role of CREB

Ottavio Arancio, Columbia University Medical Center, USA
Amyloid-beta: From Physiology to Pathology

Steffany A.L. Bennett, University of Ottawa, Canada
Phospholipid Mediators of Synaptic Dysfunction

Guojun Bu, Mayo Clinic, USA
ApoE and its Receptor in Brain Lipid Metabolism in AD

Cynthia A. Massaad, Baylor College of Medicine, USA
Short Talk: Mitochondrial Free Radicals Play a Critical Role in Alzheimer’s Disease-Related Blood Flow and Axonal Transport Deficits Pathology

09:20—09:40
Coffee Break

Kokopelli's
11:00
On Own for Lunch and Recreation

11:00—13:00
Poster Setup

Big Horn C
13:00—22:00
Poster Viewing

Big Horn C
16:30—17:00
Coffee Available

Kokopelli's
17:00—19:00
Alzheimer's Disease and Neuronal Regeneration
Meeting has ended...abstracts no longer viewable online.
Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease?

Big Horn B
* Bruce T. Lamb, Indiana University School of Medicine, USA

Frank Longo, Stanford School of Medicine, USA
Small Molecule p75 Receptor Ligands Inhibit Abeta-Induced Degeneration, Synaptic Dysfunction and Cognitive Loss

Daniel A. Peterson, Rosalind Franklin University, Chicago Medical School, USA
The Contribution of Neurogenesis in Repairing the Aging Brain

Stephen M. Strittmatter, Yale University, USA
Beyond (Downstream of) Abeta: NgR and PrP

Patrick A. Lewis, University of Reading, UK
Short Talk: Investigating Lewy Body Disease with Human Neuronal Cells

19:00—20:00
Social Hour with Lite Bites

Kokopelli's
19:30—22:00
Poster Session 2

Big Horn C

WEDNESDAY, JANUARY 13

07:00—08:00
Breakfast

Kokopelli's
08:00—11:00
Alzheimer's and the Immune System
Meeting has ended...abstracts no longer viewable online.
What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta.

Big Horn B
* Andrea J. Tenner, University of California, Irvine, USA

Richard M. Ransohoff, Biogen, USA
Microglia, Monocytes and Macrophages

Terrence Town, Cedars-Sinai University of California Los Angeles, USA
Inflammation and Innate Immunity in Alzheimer's Disease

Josef Priller, Charité – Universitätsmedizin Berlin, Germany
Bone Marrow-Derived Cells in Models of Alzheimer's Disease

Joseph El Khoury, Massachusetts General Hospital, USA
Chemokines and Mononuclear Phagocytes recruited in AD

Marie E. Benoit, University of California, Irvine regents, USA
Short Talk: Neuroprotective Pathways Stimulated by the Complement Protein C1q in Neurons

09:20—09:40
Coffee Break

Kokopelli's
11:00—13:00
Poster Setup

Big Horn C
11:00
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Big Horn C
16:30—17:00
Coffee Available

Kokopelli's
17:00—19:00
Alzheimer's and Protein Degradation
Meeting has ended...abstracts no longer viewable online.
What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation?

Big Horn B
* Terrence Town, Cedars-Sinai University of California Los Angeles, USA

Jeffery W. Kelly, The Scripps Research Institute, USA
Proteostasis

Kent B. Matlack, Whitehead Institute for Biomedical Research, USA
Using Simple Cells to Model Complex Diseases

Zhenyu Yue, Mount Sinai Medical Center, USA
Autophagy: Cell Self-Eating in Alzheimer's Disease

Gizem Donmez, Tufts University School of Medicine, USA
Short Talk: SIRT1 Suppresses Alzheimer´s Disease by Activating the Alpha Secretase Gene ADAM10 in APPswe, PSEN1dE9 Mouse Model

19:00—20:00
Social Hour with Lite Bites

Kokopelli's
19:30—22:00
Poster Session 3

Big Horn C

THURSDAY, JANUARY 14

07:00—08:00
Breakfast

Kokopelli's
08:00—11:00
Alzheimer's Disease and Diagnostics
Meeting has ended...abstracts no longer viewable online.
Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets?

Big Horn B
Daniel M. Skovronsky, Avid Radiopharmaceuticals, Inc., USA
PET Radiopharmaceuticals for Diagnosis of Dementias

Holly Soares, Bristol-Myers Squibb, USA
Multiplex Panels as Diagnostic Tools in Alzheimer’s Disease

Neill Graff-Radford, Mayo Clinic, USA
What have we learned from plasma Abeta?

* Tony Wyss-Coray, Stanford University School of Medicine, USA
The Plasma Communicome of Normal Aging and Dementia

Alice M. Wyrwicz, NorthShore University HealthSystem, USA
Short Talk: Diffusion Tensor Imaging as a Potential Biomarker of Dendritic Alterations in Mouse Models of AD

09:20—09:40
Coffee Break

Kokopelli's
11:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Kokopelli's
17:00—19:00
Alzheimer's Disease and Therapeutics
Meeting has ended...abstracts no longer viewable online.
If anti-amyloid/tau therapies work or don’t, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs?

Big Horn B
Kullervo Hynynen, Sunnybrook Health Sciences Centre, Canada
MRI Guided Ultrasound Delivery of Drugs to the CNS

Valerie Cullen, Link Medicine Corp, USA
A New Therapeutic Strategy for Neurodegeneration

* JoAnne McLaurin, University of Toronto, Canada
Small Molecule Therapy for Alzheimer's Disease

Linda J. Van Eldik, University of Kentucky, USA
Short Talk: Targeting Glia-Neuron Interactions that Result in Synaptic Dysfunction as a Drug Discovery Strategy for Alzheimer’s Disease

19:00—20:00
Social Hour with Lite Bites

Kokopelli's
20:00—23:00
Entertainment

Big Horn C

FRIDAY, JANUARY 15

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AG034733-01




We gratefully acknowledge additional support for this conference from:

Alzheimer's Drug Discovery Foundation Medivation, Inc.
Takeda Pharmaceutical Company Limited
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Avid Radiopharmaceuticals, Inc.


Genentech, Inc.


Lilly UK


Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

ACS Publications
Gerontological Society of America


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676